CD8A and neoplasm: Additionally, this study incorporated blood collections and metastatic tumour biopsies to assess immune cell dynamics following treatment, revealing differences in certain circulating immune cell subsets (e.g. CD8+ effector cells and natural killer T cells) between responding and non-responding patients.